Trovagene Expands NPM Patent Coverage

Trovagene announced the issuance of U.S. Patent 8,501,924, "Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof." The patent pertains to nucleic acid sequences encoding NPM mutants and methods of detecting them for diagnosing acute myeloid leukemia and monitoring residual AML disease.
FirstWord MedTech